CTLA4 and melanoma: Taken together, these findings suggest that further enhancement of FcγR effector function of anti-CTLA-4 may result in increased anti-tumour activity, and FcγRIIIa-158V/F polymorphism is linked to ipilimumab response in melanoma patients.